Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer
Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.
Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.
Head and Neck Microvascular Reconstructive Workshop *BRAND NEW COURSE! Tuesday, May 14, 2024 at the Hyatt Regency Chicago Explore vital harvesting techniques for a…
Valerae Lewis, M.D., is a leader in the field of orthopedic oncology and chairs MD Anderson’s Orthopaedic Oncology department. Here, she shares what led her…
An abstract is unavailable.
Fuzuloparib with or without apatinib provided superior PFS benefit vs chemotherapy in HER2– metastatic breast cancer harboring germline BRCA1/2 mutations.
PHILADELPHIA (May 8, 2024) — On April 26, 2024, Fox Chase Cancer Center welcomed staff and faculty from Temple Health to the 10th Annual Cultural…
The American Cancer Society plans to follow 100,000 healthy black women for 30 years in the largest-of-its kind study into the demographic’s long- term health…
A new study suggests that starting a patient on preferred targeted therapy within 1 year of metastatic non-small cell lung cancer diagnosis can still improve…
This site uses cookies. By continuing to use our website, you are agreeing to our privacy
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.